Challenging pharmaceutical patents : a « death spiral » for generic companies ?
I remain puzzled by an article in the Financial Times (1 Oct. 2010) which highlights recent doubts of the
I remain puzzled by an article in the Financial Times (1 Oct. 2010) which highlights recent doubts of the
(Edited version, October 11, 2013) ‘Pay for delay’ deals are commonplace in the pharmaceutical industry; they involve branded drug
Documents Programme The EC Commission’s Sector Inquiry – Start, Provess and Provisional Findings by Philipp GASPARON Patent Litigation, Disputes